Laser Therapy for Diabetic Peripheral Neuropathic Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02328911|
Recruitment Status : Withdrawn (Difficulty recruiting qualified subjects.)
First Posted : December 31, 2014
Last Update Posted : September 28, 2015
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Peripheral Neuropathy||Device: Laser treatment Device: Sham treatment||Phase 2|
The proposed study is a randomized, double-blinded clinical trial to evaluate the efficacy of a course of laser therapy on peripheral neuropathic pain in persons with diabetes. Participants will be assessed at baseline, post-intervention, and 3-months followup, and the study will consist of two treatment arms, including: (a) twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks or (b) same treatment schedule sham (or placebo) for 12 weeks. Additionally, the study will examine inflammatory markers, functional status, and quality of life.
Specific Aim 1. Change from baseline in self-reported pain in a sample of adults with diabetes at their last visit and at 3 months. Hypothesis 1: The laser therapy will produce significant improvement at post-intervention and three-month followup on measures of self-reported pain among adults with diabetes. Specific Aim 2: Decrease biochemical markers of inflammation by investigating levels of cytokines. Hypothesis 2: The laser therapy will produce significant improvement at post-intervention and three-month followup on levels of inflammatory markers.Specific Aim 3: Improve quality of life. Hypothesis 3: The laser therapy will produce significant improvement at post-intervention and three-month followup on quality of life.No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture.
Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.The proper use of the LiteCure LightForce FX Therapy Laser class IV laser therapy device should be harmless and presents no different risks than similar laser therapy devices currently on the market. At the time of this submission, no serious adverse events have been reported to the company or the regulatory authority by consumers. All study personnel will complete detailed training in the use of the device and will follow the directions of the manufacturer for operating the device; all instructions for use of the device will be followed for each subject.
As reported by LiteCure Medical the LiteCure LightForce FX therapy laser device has been cleared by the FDA, tested according IEC electrical safety standards for medical devices, and manufactured in an ISO13485 compliant facility. These certifications ensure that LiteCure Medical devices are manufactured in state of the art facilities, under strict quality control, and environmental protection standards. Participants will incur no additional appreciable psychological or social risks by participating in this study. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.
The information obtained in this study will help in determining the efficacy of using a class IV laser therapy device for neuropathic pain, inflammation, and quality of life in persons with diabetic distal symmetric peripheral neuropathy. By participating in the study, subjects may feel less pain, have lower inflammation, and experience improved quality of life. The minimal risk of participating in this study is reasonable because of the potential benefit gained in pain status, inflammatory status, and quality of life.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Laser Therapy Treatment of Peripheral Neuropathic Pain in Individuals With Diabetes|
|Study Start Date :||January 2015|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||August 2015|
Experimental: Laser treatment
Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
Device: Laser treatment
Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
Other Name: LiteCure™ LCT-1000 laser
Sham Comparator: Sham treatment
Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
Device: Sham treatment
A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
Other Name: LiteCure™ LCT-1000 laser with laser device disabled
- Change in self-reported pain. [ Time Frame: Baseline, from baseline up to 12 weeks (weekly) , and 3-month follow-up. ]Pain will be quantitatively assessed through the use of the vibration testing technique (on-off method) and the Semmes-Weinstein monofilament test .The assessment will be carried out at baseline, baseline up to 12 weeks (weekly), and at 3 months follow-up. In addition, changes in pain over the course of the study will be assessed with several questionnaires and tests, including the Visual Analogue Scale Quadruple Pain Scale, (VAS-QPS), the Neuropathic Pain Scale (NPS), and the Pain Disability Questionnaire (PDQ).
- Change in inflammation by measuring levels of biochemical markers. [ Time Frame: Baseline, from baseline up to 12 weeks (weekly) , and 3-month follow-up. ]Subjects will have blood drawn, and the tests will include a cytokine panel to check for inflammation in the body at baseline, baseline up to 12 weeks (weekly), and at 3 months follow-up.
- Change in quality of life. [ Time Frame: Baseline, from baseline up to 12 weeks (weekly) , and 3-month follow-up. ]Subjects will be asked to complete the Medical Outcomes Study Short Form 36 (SF-36) in order to assess the subjects' functional status and measure general health-related quality of life at baseline, baseline up to 12 weeks (weekly), and at 3 months follow-up.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02328911
|United States, Florida|
|University of Miami Miller School of Medicine, Clinical Research Building, Department of Psychiatry & Behavioral Sciences|
|Miami, Florida, United States, 33136|
|Principal Investigator:||John E. Lewis, Ph.D.||University of Miami|